Enanta Pharmaceuticals Files 8-K on Financials
Ticker: ENTA · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ENTA
TL;DR
Enanta Pharma filed an 8-K on Aug 11, 2025, for financial reporting.
AI Summary
Enanta Pharmaceuticals, Inc. filed an 8-K on August 11, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event.
Why It Matters
This filing is a routine disclosure for Enanta Pharmaceuticals, Inc., informing investors about their financial condition and operations.
Risk Assessment
Risk Level: low — This is a standard SEC filing for reporting financial information and does not indicate any unusual events or risks.
Key Players & Entities
- ENANTA PHARMACEUTICALS, INC. (company) — Registrant
- August 11, 2025 (date) — Date of earliest event reported
- 001-35839 (company) — Commission File Number
- 04-3205099 (company) — IRS Employer Identification No.
- 4 Kingsbury Avenue, Watertown, Massachusetts 02472 (location) — Principal Executive Offices
- (617) 607-0800 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Enanta Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
On what date was this 8-K filing reported?
The 8-K filing was reported on August 11, 2025.
What is Enanta Pharmaceuticals, Inc.'s principal executive office address?
Enanta Pharmaceuticals, Inc.'s principal executive office is located at 4 Kingsbury Avenue, Watertown, Massachusetts 02472.
What is Enanta Pharmaceuticals, Inc.'s Commission File Number?
Enanta Pharmaceuticals, Inc.'s Commission File Number is 001-35839.
What is the IRS Employer Identification Number for Enanta Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Enanta Pharmaceuticals, Inc. is 04-3205099.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2025-08-11 16:15:28
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
Filing Documents
- enta-20250811.htm (8-K) — 43KB
- enta-ex99_1.htm (EX-99.1) — 263KB
- img152620751_0.jpg (GRAPHIC) — 16KB
- 0001193125-25-177941.txt ( ) — 442KB
- enta-20250811.xsd (EX-101.SCH) — 23KB
- enta-20250811_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 11, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of Enanta Pharmaceuticals, Inc. dated August 11, 2025, reporting Enanta's financial results for the fiscal quarter ended June 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: August 11, 2025 By: /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer